EN DE
Watch Beijing SL Pharmaceutical Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Beijing SL Pharmaceutical Co Ltd (002038) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Beijing SL Pharmaceutical Co Ltd stock ¥1.24, price ¥5.15, that is 75.9% below the price, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE000001L31

BS Beijing SL Pharmaceutical Co Ltd logo Thin data Nov 6, 2026

Beijing SL Pharmaceutical Co Ltd

002038 · SHE
Very expensive, weak quality

Our calculation puts a fair price 76% below what the stock costs today.

Low debt
Generates free cash flow
0.2% dividend yield · Cash covered
Quality 47/100
Revenue last quarter 16% below a year ago.
Fair value ¥1.24 · Strongly overvalued (−75.9%)
Weak Growth (revenue 5y −10.9 %/yr in CNY)
Loss-making · -126.8% net margin (TTM)
Trails peers (3/14)
Narrow moat 12/100
Thin data
Watch Beijing SL Pharmaceutical Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥15.35 ¥4.98 Fair Value ¥1.24 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range ¥4.98 – ¥15.35 · fair‑value band ¥1.02 – ¥1.55 · the ¥5.15 price screens above the ¥1.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Beijing SL Pharmaceutical Co in your weekly email

Every Wednesday you see whether Beijing SL Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally.

Show moreShow less

The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibroblast growth factor gel; human interleukin-11; arsenic trioxide; thymopentin; paclitaxel injection; docetaxel injection; vinorelbine tartrate injection; asparaginase; calcium folinate; gemcitabine hydrochloride; regorafenib tablets; oseltamivir phosphate capsules; ornidazole injection; adefovir dipivoxil capsules/adefovir dipivoxil tablets; ribavirin; valacyclovir hydrochloride; levofloxacin hydrochlorid; tenofovir disoproxil fumarate; cyclosporin injection/cyclosporin soft capsules; mycophenolate mofetil dispersible; coenzyme complex; enoxaparin sodium; simvastatin; telmisartan amlodipine; liposon; nitroglycerin spray; eptifibatide, argatroban; voglibose; dapagliflozin; vildagliptin; granisetron hydrochloride injection; omeprazole enteric-coated capsules; adenosylmethionine butanedisulfonate; cytidine triphosphate disodium injection cytidine triphosphate disodium injection; gabapentin; risedronate sodium; salmon calcitonin injection; lucosamine sulfate capsules; loratadine dispersible; desloratadine; naftopidil; somatostatin for injection; octreotide acetate; and etodolac sustained-release tablets.

The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is headquartered in Beijing, the People's Republic of China.

Stock analysis

Beijing SL Pharmaceutical Co Ltd (002038) currently trades at ¥5.15, while our model-based Fair Value estimate is ¥1.24, 76% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ¥1.93 per share, and 0 of the 10 models we run sit above the ¥5.15 price.

Bear case: the Asset-Based group reads lowest at ¥1.17, and 10 of the 10 models stay below the price. Data coverage for this calculation is low.

Scenario range: ¥1.02 (bear) to ¥1.55 (bull), the price of ¥5.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Beijing SL Pharmaceutical Co Ltd reported revenue of 624M CNY in FY2025 versus 1.2B CNY in FY2021, a compound −15.4%/yr. Reported net income was −347M CNY in FY2025.

Key figures

Market cap 5.3B CNY (≈ $794M) Small · P/S ratio 9.13 · EPS (TTM) ¥−0.7100 · Dividend yield 0.2% · Net margin −127% · Return on equity −13.6% · Return on assets (EBIT) 3.6% (5-year average) · Operating margin −30.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 43% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −76%, 002038 screens richer than that median.

Fair Value models

Bear ¥1.02 Fair Value ¥1.24 Bull ¥1.55
Price ¥5.15 · Downside -75.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ¥1.00 ¥1.13 ¥1.33 82
Growth DCF ¥1.01 ¥1.13 ¥1.30 80
5Y EBITDA Exit ¥1.53 ¥2.11 ¥2.84 76
All 10 models by family
DCF Models
FCF DCF ¥1.00 ¥1.13 ¥1.33 82
5Y Revenue Exit ¥1.02 ¥1.24 ¥1.55 74
5Y EBITDA Exit ¥1.53 ¥2.11 ¥2.84 76
10Y Revenue Exit ¥0.9900 ¥1.17 ¥1.37 68
10Y EBITDA Exit ¥1.28 ¥1.67 ¥2.13 70
Multiples
EV/EBITDA ¥2.08 ¥2.64 ¥3.20 67
EV/Revenue ¥0.9700 ¥1.22 ¥1.47 54
Asset-Based
NCAV (Graham) ¥0.7700 ¥1.17 ¥1.46 54
Growth DCF
Growth DCF ¥1.01 ¥1.13 ¥1.30 80
Rev-Margin DCF ¥1.02 ¥1.25 ¥1.53 74

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 18
Are margins and returns getting better?
Cashflow 50
Do the profits arrive as real cash?
Financial strength 82
Debt, balance sheet and risk of trouble
Investment 65
Does it invest with discipline instead of growing at any price?
Low Volatility 55
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 92
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 17/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.9%
Start year 2020 (pandemic). Over 10 years: −6.0% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
27.6% (2019) → −0.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+39.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +37.4% a year for the price.

002038 screens overvalued: fair value 76% below the price. Compare with Merck KGaA →

Compare Beijing SL Pharmaceutical Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −75.9% · Bottom 25%
Profitability
Return on assets −5.7% · Bottom 25%
Net margin (12 months) −126.8% · Bottom 25%
Operating margin (12 months) −30.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −15.7% · Bottom 25%
Dividend yield (12 months) 0.2% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.02× · Cheaper than median
P/S (12 months) 9.28× · Priciest 25%
Price / free cash flow (fiscal year) 81.8× · Priciest 25%
EV/EBITDA 32.9× · Priciest 25%
PEG 0.67× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)4 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs 002038
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 002038
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 002038
Haleon plc HLN $9.14 $8.61 −6% vs 002038
Merck KGaA MRK €148.75 €109.18 −27% vs 002038
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 002038
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 002038
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 002038
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 002038
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 002038

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beijing SL Pharmaceutical Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Beijing SL Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002038

Frequently asked questions

Is Beijing SL Pharmaceutical Co Ltd (002038) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ¥1.24 versus a price of ¥5.15, about 76% lower (overvalued).
What is the fair value of 002038?
Our model-based fair value for Beijing SL Pharmaceutical Co Ltd is ¥1.24 (as of Nov 6, 2026), built from audited fundamentals. The current price: ¥5.15.
What is the quality score of 002038?
Beijing SL Pharmaceutical Co Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing SL Pharmaceutical Co Ltd (002038)?
Our model-based price target is the fair value of ¥1.24 (as of Nov 6, 2026) from 10 valuation models. Cautious scenario ¥1.02, optimistic scenario ¥1.55. It is a calculation from audited fundamentals, not an analyst target.
What is the Beijing SL Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥1.24, about 76% lower versus a price of ¥5.15 (overvalued). Cautious scenario ¥1.02, optimistic scenario ¥1.55. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing SL Pharmaceutical Co Ltd (002038)?
Beijing SL Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 570M CNY (latest available figure, as of Nov 6, 2026).
Does Beijing SL Pharmaceutical Co Ltd pay a dividend?
Beijing SL Pharmaceutical Co Ltd currently shows a dividend yield of 0.19% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Beijing SL Pharmaceutical Co Ltd (002038) and when is the ex-dividend date?
Beijing SL Pharmaceutical Co Ltd pays a dividend of ¥0.01 per share a year, a dividend yield of 0.2%. The last ex-dividend date was Jul 22, 2026. A dividend has been paid every year since at least 2005. Free cash flow covers the dividend 6.30 times. Our assessment: Cash covered. The dividend is fully funded by free cash flow. The payout ratio on earnings is not available for this company.
What growth is priced into Beijing SL Pharmaceutical Co Ltd (002038)?
For today's price to be fair in a discounted-cash-flow model, Beijing SL Pharmaceutical Co Ltd would have to grow free cash flow by +39.7 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -10.9 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 002038 use?
Our models discount Beijing SL Pharmaceutical Co Ltd at 11.9 %: a base by market capitalisation (small), country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Beijing SL Pharmaceutical Co Ltd that is +39.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Beijing SL Pharmaceutical Co Ltd (002038) delivered so far?
Over the past 5 years revenue at Beijing SL Pharmaceutical Co Ltd grew -10.9 % a year. The price currently implies free-cash-flow growth of +39.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Beijing SL Pharmaceutical Co Ltd (002038) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Beijing SL Pharmaceutical Co Ltd (+39.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Beijing SL Pharmaceutical Co Ltd (002038)?
The free-cash-flow yield on the price is 1.22 %: that much free cash flow Beijing SL Pharmaceutical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Beijing SL Pharmaceutical Co Ltd (002038)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing SL Pharmaceutical Co Ltd it is ¥1.24 per share (as of Nov 6, 2026), against a price of ¥5.15. It is the blended result of 10 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Beijing SL Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 002038 trades above its calculated fair value: price ¥5.15, fair value ¥1.24, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002038?
No. The price is what the market pays today (¥5.15); the fair value is what the company's own numbers justify (¥1.24). For Beijing SL Pharmaceutical Co Ltd the two are ¥3.91 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing SL Pharmaceutical Co Ltd worth?
The market values Beijing SL Pharmaceutical Co Ltd at about 5.3B CNY (market capitalisation, as of Nov 6, 2026). Per share that is ¥5.15; our models calculate a fair value of ¥1.24 per share.
What do the bullish and bearish scenarios say about 002038?
Our models span a range for Beijing SL Pharmaceutical Co Ltd: cautious scenario ¥1.02, base ¥1.24, optimistic ¥1.55 per share (as of Nov 6, 2026, price ¥5.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of 002038?
The PEG ratio of Beijing SL Pharmaceutical Co Ltd is 0.67 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Beijing SL Pharmaceutical Co Ltd (002038)?
Balance-sheet figures for Beijing SL Pharmaceutical Co Ltd (as of Nov 6, 2026): return on equity −13.6%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 002038 from its 52-week high?
Beijing SL Pharmaceutical Co Ltd trades at ¥5.15, about 43% below its 52-week high of ¥8.96 and 3% above the low of ¥4.98 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.24 is for.
Which stocks are comparable to Beijing SL Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing SL Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price ¥5.15, calculated fair value ¥1.24 (−76%), Quality Score 47/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002038 calculated?
We run Beijing SL Pharmaceutical Co Ltd through 10 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of ¥1.24 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Beijing SL Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing SL Pharmaceutical Co Ltd (002038)?
The closing price on Nov 6, 2026 was ¥5.15. Our model-based fair value is ¥1.24, about 76% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing SL Pharmaceutical Co Ltd right now?
The price sits above even our optimistic bull case (¥1.55). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Beijing SL Pharmaceutical Co Ltd (002038) come from?
Earnings per share at Beijing SL Pharmaceutical Co Ltd grew −7.2 % a year from 2013 to 2024. Broken into its drivers: revenue per share −1.5 %, EBIT margin −5.6 %, tax rate +0.4 %, residual (interest, one-offs) −0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Beijing SL Pharmaceutical Co Ltd

How large is the market capitalisation of Beijing SL Pharmaceutical Co Ltd (002038)?
The market capitalisation of Beijing SL Pharmaceutical Co Ltd is 5.3B CNY (≈ $794M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing SL Pharmaceutical Co Ltd (002038)?
The price-to-sales ratio of Beijing SL Pharmaceutical Co Ltd is 9.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beijing SL Pharmaceutical Co Ltd (002038)?
Earnings per share at Beijing SL Pharmaceutical Co Ltd are ¥−0.7100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Beijing SL Pharmaceutical Co Ltd (002038)?
The dividend yield of Beijing SL Pharmaceutical Co Ltd is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Beijing SL Pharmaceutical Co Ltd (002038)?
The net margin of Beijing SL Pharmaceutical Co Ltd is −127% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beijing SL Pharmaceutical Co Ltd (002038)?
The return on equity (ROE) of Beijing SL Pharmaceutical Co Ltd is −13.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing SL Pharmaceutical Co Ltd (002038)?
On an EBIT basis the return on assets of Beijing SL Pharmaceutical Co Ltd is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing SL Pharmaceutical Co Ltd (002038)?
The operating margin of Beijing SL Pharmaceutical Co Ltd is −30.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing SL Pharmaceutical Co Ltd (002038)?
Revenue at Beijing SL Pharmaceutical Co Ltd is growing −15.7% versus a year earlier (3y avg −15.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Beijing SL Pharmaceutical Co Ltd (002038)?
Earnings per share at Beijing SL Pharmaceutical Co Ltd are growing −42.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Beijing SL Pharmaceutical Co Ltd (002038) hold?
Beijing SL Pharmaceutical Co Ltd holds more cash than debt, 412M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Beijing SL Pharmaceutical Co Ltd in the live analysis

One click puts Beijing SL Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.